Biochemical recurrence after radical prostatectomy and postoperative radiotherapy: current evidence and controversial issues
BCR after radical prostatectomy and postoperative radiotherapy represents a challenge in PCa management. Risk stratification is key for guiding the addition of ARPIs to standard ADT. PSMA PET may further refine tailored strategies such as MDT, whose promising efficacy needs further exploration. Ongoing trials will clarify treatment sequencing and patient selection in the evolving paradigm of BCR management.
Authors
- Markus Graefen (ORCID: https://orcid.org/0000-0003-3609-3512)
- Fabian Falkenbach (ORCID: https://orcid.org/0000-0003-1907-3982)
- Giorgio Gandaglia (ORCID: https://orcid.org/0000-0002-5052-721X)
- Tobias Maurer (ORCID: https://orcid.org/0000-0002-5660-7691)
- Mattia Longoni (ORCID: https://orcid.org/0000-0002-2613-2306)
- Francesco Montorsi
- Pierre I. Karakiewicz
- Alberto Briganti
Institutions
- Vita-Salute San Raffaele University (IT)
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
- IRCCS Ospedale San Raffaele (IT)
- Université de Montréal (CA)
Publication Details
- Journal
- Current Opinion in Urology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1097/mou.0000000000001292
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.07